Effects of genetic polymorphisms of the renin-angiotensin system in children with nephrotic syndrome

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 3, 2005, Pages 138-144

  Tabel, Yilmaz ^a,b   Berdeli, Afig ^a   Mir, Sevgi ^a   Serdaroǧlu, Erkin ^a   Yilmaz, Ebru ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Children; Gene polymorphism; Nephrotic syndrome; Ras

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; PREDNISOLONE; STEROID;

ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

BIOPSY; CHILD; EDEMA; FEMALE; GENOTYPE; HUMANS; MALE; NEPHROTIC SYNDROME; RENIN-ANGIOTENSIN SYSTEM;

EID: 33144471728     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.020     Document Type: Article

References (42)

1. Clark AG, Barrat TM. Steroid-responsive nephrotic syndrome. In: Barrat TM, Avner ED, Harmon WE (eds) Pediatric nephrology. Lipincott Williams and Wilkins, Baltimore, 1999; pp 731-46.
2. Cortes L, Tejani A. Dilemma of focal segmental glomerular sclerosis. Kidney Int 1996;53:S57-S63.
3. Boyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal segmental glomerular sclerosis. Eds: Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E and Winerals CG. Oxford Textbook of Clinical Nephrology, Oxford University Press, 1998.
4. Luther Y, Bantis C, Ivens K et al. Effects of the genetic polymorphisms of the renin-angiotensin system on focal segmental glomerulosclerosis. Kidney Blood Press Res 2003;26:333-7.
5. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-8.
6. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996;49:578-97.
7. Frishberg Y, Becker-Cohen R, Halle D et al. Genetic polymorphisms; of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney International 1998;54:1843-9.
8. Oktem F, Sirin A, Bilge I, Emre S, Agachan B, Ispir T. ACE I/D gene polymorphism in primary FSGS and steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2004;19:384-9.
9. Rigat B, Hubert C, Alhenc-Gelas F, Rodby R, Gunnels JC, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
10. Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
11. Jeunemaitre X, Soubrier F, Koteletsev YV et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992;71:169-80.
12. Schmidt S, Sharma AM, Zilch O et al. Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Nephrol Dial Transplant 1995;10:1145-8.
13. Morise T, Takeuchi Y, Takeda R. Rapid detection and prevalence of the variants of the angiotensinogen gene in patients with essential hypertension. J Intern Med 1995;237:175-80.
14. Caulfield M, Lavender P, Farral M et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994;330:1629-33.
15. Hingorani AD, Sharma P, Jia H, Hopper R, Brown MJ. Blood pressure and the M235T polymorphism of the angiotensinogen gene. Hypertension 1996;28:907-11.
16. Fogarty DG, Harron JC, Hughes AE, Doherty CC, Maxwell AP. The association of an angiotensinogen variant with diabetic nephropathy. (abstract) J Am Soc Nephrol 1995;6:449.
17. Schmidt S, Strojek K, Grzeszczak W, Ganten D, Ritz E. The M235T variant of the angiotensinogen gene and nephropathy in type 2 diabetes. (abstract) J Am Soc Nephrol 1995;6:1047.
18. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990;4:303-37.
19. International study of kidney disease in children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at the time of diagnosis. Kidney International 1978;13:159-65.
20. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. Pediatrics 1996;98:649-58.
21. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571-90.
22. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235Thr allele of the human angiotensinogen gene. Hum Mol Genet 1993;2(5):609-10.
23. Seikaly MG, Arant BS, Seney FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments in the rat. J Clin Invest 1990;86:1352-7.
24. Wolf G, Bytzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:3-13.
25. Wiecek A, Chudek J, Kokot F. Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications. Nephrol Dial Transplant 2003; 18(suppl 5):16-20.
26. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group. The effects of angiotensin-converting enzyme inhibition of diabetic nephropathy. N Engl J Med 1993;329:1456-62.
28. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effects of antihypertensive therapy on the kidney in patients with diabetes: A metaregression analysis. Ann Intern Med 1993;118:129-38.
29. Geiger H. Are angiotensin II receptor blockers; superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997;12:640-2.
30. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans. Kidney Int 1996;50:684-92.
31. Johnston CL. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-07.
32. Ziai F, Ots M, Provoost AP et al. The angiotensin receptor antagonists, irbesartan, reduces renal injury of experimental chronic renal failure. Kidney Int 1996;50(suppl. 57):132-6.
33. Pollock DM, Divish BJ, Polakowski JS, Oppgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Farmachol Exp Ther 1993;267:657-63.
34. Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-9.
35. Lee DY, Kim W, Kang SK, Koh GY, Park SK. Angiotensin-converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis. Nephron 1997;77:471-3.
36. Al-Eisa A, Haider MZ, Srivastva BS. Angiotensin-converting enzyme gene insertion/deletion polymorphism in idiopathic nephrotic syndrome in Kuwaiti Arab children. Scand J Urol Nephrol 2001;35:239-42.
37. Harden PN, Geddes C, Rowe PA et al. Polymorphism in angiotensin converting enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540-2.
38. Marre M, Jeunmaitre X, Gallois Y et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 1997;99:1585-95.
39. Hostteter TH, Olson JL, Rennke HG, Venkatachalam VA, Brenner BM. Hiperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:85-95.
40. Brenner BM. Nephron adaptation to renal ablation and injury. Am J Physiol 1985;249:324-37.
41. Remuzzi G, Ruggenenti P, Benigni A. Pathophysiology of progressive nephropathy. Kidney Int 1997;51:2-15.
42. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal disease: Theory and practice. J Am Soc Nephrol 1996;7:2025-43.